Puma Biotechnology (PBYI) Non Operating Income (2011 - 2026)
Puma Biotechnology's (PBYI) quarterly Non Operating Income came in at $401000.0 in Q1 2026, up 155.93% YoY from $156685.0 in Q1 2025, and up 40000.0% on a QoQ basis from $1000.0 in Q4 2025.
Puma Biotechnology (PBYI) Non Operating Income (2011 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 16 years of Non Operating Income data on file, last reported at $401000.0 in Q1 2026.
- Quarterly Non Operating Income rose 155.93% year-over-year to $401000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$399000.0 (up 92.45% YoY) and the FY2025 annual result came in at -$1.5 million, up 77.91% from the prior year.
- Non Operating Income climbed to $401000.0 in Q1 2026, from $1000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $401000.0 in Q1 2026 to a low of -$15.3 million in Q4 2022.
- A 5-year average of -$2.4 million and a median of -$2.0 million in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income tumbled 539.73% — and 2026, when it jumped 155.93%.
- Tracing PBYI's Non Operating Income over 5 years: stood at -$15.3 million in 2022, then jumped by 86.99% to -$2.0 million in 2023, then jumped by 43.48% to -$1.1 million in 2024, then soared by 100.09% to $1000.0 in 2025, then soared by 40000.0% to $401000.0 in 2026.
- The last three Non Operating Income figures came in at $401000.0 (Q1 2026), $1000.0 (Q4 2025), and -$330000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 660,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 660,000.00 |
| Mar 31, 2026 | 401,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | -330,000.00 |
| Jun 30, 2025 | -471,000.00 |
| Mar 31, 2025 | -717,000.00 |
| Dec 31, 2024 | -1.13 Mn |
| Sep 30, 2024 | -1.47 Mn |
| Jun 30, 2024 | -1.97 Mn |
| Mar 31, 2024 | -2.30 Mn |
| Dec 31, 2023 | -1.99 Mn |
| Sep 30, 2023 | -2.58 Mn |
| Jun 30, 2023 | -2.58 Mn |
| Mar 31, 2023 | -2.82 Mn |
| Dec 31, 2022 | -15.33 Mn |
| Sep 30, 2022 | -2.69 Mn |
| Jun 30, 2022 | -2.63 Mn |
| Mar 31, 2022 | -2.62 Mn |
| Dec 31, 2021 | -2.40 Mn |
| Sep 30, 2021 | -35.68 Mn |